Abstract
Considerable effort has led to an increased interest in emerging preclinical and clinical data regarding the pathophysiological changes in the posttraumatic brain. It is widely believed that delayed cell damage and death contributes to behavioral impairment following traumatic brain injury. However, no drug therapy to attenuate this process is available at present, and the development of new therapeutic regimen is urgently warranted. This manuscript represents a compendium of recent preclinical work undertaken to evaluate new pharmacologic strategies in the experimental setting as a first step towards the development of a therapeutic armamentarium directed to improve functional recovery in head-injured patients.
Keywords: Pharmacology therapy, Traumatic brain injury, Cation homeostasis, Glutamate antagonists, Calpain antagonists, Cytoskeleton, Nitric oxide, Nitric oxide synthetase, Free rasical scavengers, Lipid peroxidation
Current Pharmaceutical Design
Title: Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies
Volume: 7 Issue: 15
Author(s): H. L. Laurer and T. K. McIntosh
Affiliation:
Keywords: Pharmacology therapy, Traumatic brain injury, Cation homeostasis, Glutamate antagonists, Calpain antagonists, Cytoskeleton, Nitric oxide, Nitric oxide synthetase, Free rasical scavengers, Lipid peroxidation
Abstract: Considerable effort has led to an increased interest in emerging preclinical and clinical data regarding the pathophysiological changes in the posttraumatic brain. It is widely believed that delayed cell damage and death contributes to behavioral impairment following traumatic brain injury. However, no drug therapy to attenuate this process is available at present, and the development of new therapeutic regimen is urgently warranted. This manuscript represents a compendium of recent preclinical work undertaken to evaluate new pharmacologic strategies in the experimental setting as a first step towards the development of a therapeutic armamentarium directed to improve functional recovery in head-injured patients.
Export Options
About this article
Cite this article as:
Laurer L. H. and McIntosh K. T., Pharmacologic Therapy In Traumatic Brain Injury: Update On Experimental Treatment Strategies, Current Pharmaceutical Design 2001; 7 (15) . https://dx.doi.org/10.2174/1381612013397285
DOI https://dx.doi.org/10.2174/1381612013397285 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signs and Related Mechanisms of Ethanol Hepatotoxicity
Current Drug Abuse Reviews Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs
Current Pharmaceutical Design Relative Hypermetabolism of Vermis Cerebelli in Traumatic Brain Injured Patients Studied with 18FDG PET: A Descriptor of Brain Damage and a Possible Predictor of Outcome
Current Radiopharmaceuticals Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry Aggressive Antioxidant Reductive Stress Impairs Brain Endothelial Cell Angiogenesis and Blood Brain Barrier Function
Current Neurovascular Research Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Suppression of Inflammatory and Allergic Responses by Pharmacologically Potent Fungus Ganoderma lucidum
Recent Patents on Inflammation & Allergy Drug Discovery The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Increased Serum Endotoxin and Elevated CD14 and IL-1β Expression in a Rat Model of Cerebrogenic Multiple Organ Dysfunction Syndrome
Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology A Magnetic Resonance Spectroscopy Study of Lovastatin for Treating Bipolar Mood Disorder: A 4-Week Randomized Double-Blind, Placebo- Controlled Clinical Trial
Recent Patents on Inflammation & Allergy Drug Discovery